KPRX

Kiora is a pre-revenue, clinical-stage ophthalmology company whose entire value rests on two Phase 2 assets: KIO-301 (photoswitch for retinitis pigmentosa, ABACUS-2, dosing began Q3 2025) and KIO-104 (DHODH inhibitor for retinal inflammation, dosing began Q3 2025). The FY2024 flash of $16.0M revenue and +$3.59M net income was a one-off — almost certainly milestone/collaboration recognition tied to the January 2024 Théa (TOI) deal — and FY2025 reverted straight back to $0.00 revenue and a -$10.8M net loss. There is no product, no recurring revenue line, and a -$154M accumulated deficit. This is a lottery ticket on clinical readouts, not a business with earnings to value.

The balance sheet is the disqualifier. Cash of $8.70M against FY2025 operating cash burn of -$9.96M implies well under twelve months of runway at the current pace, even as R&D spend rose 37.5% to fund the two Phase 2 studies. Management is a 'clinical-stage specialty pharmaceutical company' still years from any commercialization, so the near-certain path is a dilutive raise — shares already grew 31.7% to just 3.95M, and further issuance into a ~$2.63 stock (market cap only ~$10M) would be punishing. Liabilities/equity of 0.50x looks benign, but equity itself shrank 37.4% and is being eroded by cash losses, not leverage. ROE of -67.2% simply reflects burning equity with nothing coming in.